Abstract: The present invention concerns the use of an adsorbent material modified with polynuclear metal oxyhydroxides for the selective elimination of inorganic phosphate from liquids, in particular from body fluids containing protein such as whole blood, plasma, liquid contents of the intestine as well as from dialysis fluid, as well as a process for the production of a pharmaceutical agent for oral application for the selective removal of inorganic phosphate in which an adsorbent material used according to the present invention, as such or pressed into powder form, is coated with a layer resistant to gastric acid or dispensed into an acid-resistant capsule. In order to selectively eliminate inorganic phosphate in an extracorporeal perfusion system, a body fluid such as whole blood or plasma is passed over one of the adsorbent materials.

Abstract: Meconium State Pregnancy is diagnosed by analysis of prenatal maternal fluids for the presence of specific meconium antigens, including a specific meconium protein antigen of approximately 14 KD.

Abstract: The present invention provides processes for isolating in substantially purified form water-soluble penicillin binding protein 2a of Staphylococcus aureus.

Abstract: A protein which inhibits milk secretion by lactating cows and which is present in the second (2A) significant peak when a nominally 10-30 KDa fraction of the whey proteins of the milk is resolved on a "Mono Q" anion exchange column using 10 mM imidazole buffer, pH 7.0 and a sodium chloride elution gradient. Its pI by isoelectric focussing in a gel tube is 4.8 to 5.0.

Abstract: In a process for the purification of cytokeratin 20 (CK 20), a cytoskeletal fraction of cells containing CK 20 is produced, the proteins present therein are separated by gel electrophoresis or/and by chromatography and the CK 20 is isolated from the gel or the chromatographic fraction containing CK 20. In a process according to the present invention for the production of antibodies specific for CK 20, purified CK 20 is used for the immunization and then polyclonal or monoclonal antibodies are produced according to well-known methods. These antibodies are used for the immunologically identification of CK 20, or its .alpha.-helical central fragment obtained by proteolytic cleavage on tissue sections, in tissue homogenates and in body fluids.

Abstract: Novel sorbents and methods for removing small hydrophobic and amphophilic molecules from biological fluids were disclosed. The methods and materials were particularly useful for removing viral inactivating agents from blood and blood fractions. The novel sorbents comprise a porous mineral oxide matrix having its interior porous volume substantially filled with a crosslinked hydrophobic polymer network.

Abstract: Interleukin 1 has been purified by use of various techniques including ion exchange chromatography and dye-ligand affinity chromatography. By these techniques, interleukin 1 has been purified to homogeneity. The high purification of interleukin 1 has enabled the amino acid composition of this protein to be ascertained and its amino acid sequence to be partially determined.

Abstract: The invention relates to proteinaceous compositions capable of modulating the development of erythroid progenitors such as obtainable from a biological material selected from bone marrow culture supernatants, or kidney cell lysates by contacting said biological material with a specific ligand for the proteinaceous compositions, desorbing said proteinaceous compositions and recovering same by elution. Said compositions are useful in therapeutics.

Abstract: The invention relates to substantially pure transfer factor with a specific activity of at least 5000 units per absorbance unit at 214 nm. The present invention also relates to a process for preparing the transfer factor from cell lysates. The present invention includes the use of substantially pure transfer factor with a specific activity of at least 5000 units per absorbance unit at 214 nm to treat infectious diseases.

Abstract: The invention provides a method of separating a biomacromolecule which comprises the steps of providing a separation system including a filter element which comprises a composite filtration medium, the composite filtration medium comprising a filtration layer on the upstream surface of which are located insoluble stationary phase particulates, the particulates being capable of binding to a biomacromolecule or class of biomacromolecules, a reservoir containing a solution mixture comprising at least one biomacromolecule as solute, and a pump and associated tubing to form a closed loop assembly, and recirculation pumping the solution mixture through the filter cartridge so as to bind the at least one biomacromolecule to the stationary phase particulate so as to form a biomacromolecule:stationary phase particulate product.

Abstract: A substantially pure non-glycosylated human interleukin-2 protein having a specific activity of not less than 10.sup.4 U/mg is obtained by growing a transformant carrying a DNA having a base sequence coding for human interleukin-2 to cause production and accumulation of human interleukin-2 in the culture broth, subjecting the thus obtained human interleukin-2-containing liquid to a purification process comprising a hydrophobic column chromatography.

Abstract: A biochemically pure polypeptide(s), termed osteogenic growth polypeptide (OGP), which exhibits stimulatory effects on osteoblastic cells, in vivo bone formation and hemopoietic reconstruction. OGP, identified from regenerating bone marrow, has an amino acid sequence ofAla-Leu-Lys-Arg-Gln-Gly-Arg-Thr-Leu-Tyr-Gly-Phe-Gly-Gly.

Abstract: Ala-Glu-IGF-I is a novel compound which exerts IGF-I activity and is a precursor for the preparation of IGF-I. Ala-Glu-IGF-I may by converted to IGF-I by renaturation after recombinant production in E. coli under specified conditions and then cleaving Ala-Glu from the IGF-I.

Abstract: An eliminating agent used for the measurement of the amount of glycosylated hemoglobins in a blood sample is provided. The eliminating agent comprises condensed phosphoric acids and/or the salts thereof as the main ingredient, wherein the agent eliminates labile glycosylated hemoglobin A.sub.1c into non-glycosylated hemoglobin and glucose. There is also provided a reagent comprising the eliminating agent and a hemolysis agent, which is used for the measurement of the amount of glycosylated hemoglobins; and an eluent comprising the eliminating agent, which is used for the separation of glycosylated hemoglobins in blood samples by ion-exchange chromatography to measure the amount of the glycosylated hemoglobins. A method for measuring the amount of glycosylated hemoglobin A.sub.1c in a blood sample involves the use of the eliminating agent, the reagent comprising the eliminating agent and the hemolysis agent, and/or the eluent.

Abstract: Mammalian adipogenic factors, including purified proteins or glycoproteins, capable of inducing the adipose differentiation of adipogenic cells are disclosed, as are antibodies to such proteins, DNA encoding the proteins and host cells expressing the proteins. A method for determining the susceptibility of a subject to obesity by measuring the levels of one or more adipogenic factors in a biological fluid or tissue extract is also disclosed, as is a method for evaluating an anti-obesity drug which comprises contacting the drug with cells capable of producing one or more adipogenic factors and measuring the amount of the factors produced.

Abstract: Disclosed is a primary chromatographic support containing an immobilized flocculating agent for use as a separation media for a secondary support consisting of microparticles used in affinity separation and heterogeneous immunoassays. In a specific embodiment, a flocculating agent such as polyethyleneimine is immobilized on a chromatographic resin packed in a column. The column so formed is then used to trap microparticles having an affinity ligand or binder for the ligand affixed thereon. Such microparticles are used as a solid support for the affinity reaction involved in a variety of immunoassay formats.

Abstract: A substantially pure receptor with binding activity for rhinoviruses of the small receptor group is disclosed, which has the following characteristics:(a) a molecular weight of 120 kD on a polyacrylamide gel in the presence of SDS;(b) a sedimentation constant, determined by sucrose gradient centrifugation in the presence of detergents, corresponding to about 28.4 S;(c) is bound by Lens culinaris lectin;(d) is not bound by heparin-sepharose;(e) is bound irreversibly to an anion exchanger;(f) has binding activity which is insensitive to neuraminidase;(g) consists of sub-units connected by intermolecular disulfide bridges;(h) shows no binding activity to rhinoviruses in the presence of EDTA; and(i) has a binding activity to rhinoviruses which is only slightly influenced by iodoacetamide.A receptor subunit of the above-described receptor, produced by complete reduction of said receptor, is also disclosed.

Abstract: A substantially pure heterotrimeric laminin variant comprising the structure M-X-B2, wherein M is the M polypeptide of merosin; X is selected from the group consisting of the B1 chain of laminin and S-laminin; and B2 is the B2 chain of laminin.

Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins yard fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.

Abstract: Hemoglobin is purified from a crude solution thereof, to obtain an aqueous solution containing at least 99% of a preselected hemoglobin species, by a two stage displacement chromatography process. One of the stages is conducted under anionic exchange conditions, and the other under cationic exchange conditions. In both stages, the exchange column is overloaded to displace the hemoglobin species therefrom with contaminants having greater affinity for the column, and using the impure hemoglobin solution as the displacer. Normally, anionic exchange is conducted first, with contaminants more acidic than the hemoglobin displacing the hemoglobin from the column and themselves remaining attached to the column for separation. The cationic exchange process is conducted second, on the eluent from the first column, and in this stage, the more basic contaminants displace the hemoglobin from the column under overload conditions, to yield a substantially pure hemoglobin solution.

Abstract: The invention pertains to pure, native dystrophin of mammalian skeletal muscle and a method of purifying dystrophin from mammalian skeletal muscle. The invention further pertains to a method of diagnosing muscular dystrophy by detecting the loss or abnormal structure of pure, native dystrophin from mammalian skeletal muscle. The detection of a loss of dystrophin or an abnormal structure of dystrophin is indicative of muscular dystrophy.

Abstract: This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecule proteins.

Abstract: An interleukin-2 preparation suitable for pharmaceutical purposes, consisting essentially of disialilated glycosylated interleukin-2, monosialilated glycosylated interleukin-2, or a mixture thereof, and substantially free of organic solvents, is isolated from recombinant CHO cells transformed with a vector containing a DNA sequence coding for a natural precursor of human interleukin-2, and is purified by a multi-step process.

Abstract: The protein doublet H110D, the individual components thereof, and the production and use thereof in a vaccine against a nematode infection. This protein doublet is a plasma membrane-associated protein material of the intestinal microvilli of Haemonchus contortus. H110D has a molecular weight of about 110 kd and reacts with antibodies raised in animals injected with a contortin-enriched fraction. Injection of preparations of the protein doublet H110D or its components induces the production of specific protective antibodies.

Abstract: Activin is administered systemically and locally to induce the growth of mature bone. Activin enhances the level of bone formation and the quality of the bone formed when administered locally with BMP or bone marrow. Administration of activin by subcutaneous route promotes systemic increase in the bone mass.

Abstract: The invention relates to a method of producing virus-safe highly purified factor VIII. The method includes a combination of the following measures:a) chromatographic purification of a factor VIII-containing fraction,b) tenside treatment of factor VIII in an aqueous solution at a tenside/protein ratio of from 1:1 to 1000:1, andc) heat treatment of the factor VIII preparation in the solid state.

Abstract: The present invention relates to the development of bone growth factors as therapeutics for the prevention and treatment of pathological conditions involving bone tissue. The present invention provides biologically active proteinaceous factors comprising polypeptides containing the amino acid sequence M-A-G-L-G-D-E-F-G-D, [SEQ ID NO: 1], (X) F E T L F G A/V E D V I/D A L Q F V C G D, [SEQ ID NO: 2], or A-Y-I-P-I-E-T-L-E-G-I/G-E-L-V-D/Q-T-G/L-Q-F, [SEQ ID NO: 3], or biologically active fragments or sequence analogues thereof. Among the biological properties of the proteinaceous materials of the present invention is the capability to promote the growth and/or differentiation of osteoblastic cells.

Abstract: A method of screening for cancer-associated retinopathy including the steps of acquiring a purified aliquot of 26 kDa protein, and, utilizing this protein, or peptides derived therefrom, performing a patient-serum assay to identify in a sample of a patient's serum the presence of autoantibodies to the 26 kDa protein autoantigen.

Abstract: For the quantitative selective removal or/and preparative isolation of tumour necrosis factor (TNF) or/and lipopolysaccharides from aqueous liquids, in particular blood, plasma or serum, the aqueous liquid is passed over an adsorption material which consists of a porous supporting material to which functional groups made of synthetic or/and semisynthetic or/and natural polyanion chains and namely in a linear or branched form, are covalently bound and if desired, the molecules chromatographically separated in this way are eluted from the adsorption material using a saline solution.

Abstract: Methods are provided for the isolation and purification of recombinant lung surfactant protein. The methods involve a multistep procedure including extraction with a C.sub.1 -C.sub.4 aliphatic alcohol and chromatographic purification steps which employ a C.sub.1 -C.sub.4 aliphatic alcohol as eluant. Purified proteins obtained using the disclosed isolation and purification steps are provided as well.

Abstract: An adsorption material for selectively removing Lp(a) lipoprotein, LDL cholesterol and/or vLDL cholesterol from aqueous liquids, in particular from blood, plasma or serum, consisting of porous glass beads as the solid carrier material whose silanol groups present on its surface carry ligands which are covalently bound and have alkyl residues with 4 to 12 atoms containing at least one ether group and a terminal .alpha.,.beta.-diol group containing alkyl residues with 4 to 12 C atoms and wherein the material has no free silanol groups. Also disclosed is a method of using the adsorption material for selective removal or determination of Lp(a) lipoprotein, LDL cholesterol or/and vLDL cholesterol from aqueous liquids, and a device for use in such methods.

Abstract: A process for facilitating the reconstitution of lyophilized Factor VIII complex compositions, and compositions of Factor VIII complex, which are readily reconstituted. The process of the present invention comprises providing a purified Factor VIII complex preparations; adding a stabilization agent comprising arginine; lyophilizing the stabilization agent-Factor VIII complex solutions; and reconstituting the lyophilized stabilization agent-Factor VIII complex by contacting it with solvent for less than one minute.

Abstract: A process is provided for the purification of pertussis toxin (PT) and/or filamentous hemagglutinin antigen (FHA) from a B. pertussis fermentation broth or cell free culture supernatant containing at least one antigen, which comprises contacting the fermenation broth or cell free culture supernatant with a hydroxyapatite adsorbent for a sufficient time to adsorb the antigen(s) at a pH which both PT and FHA are adsorbed and eluting a mixture containing the adsorbed antigen(s) from the adsorbent with eluant at a pH which both PT and FHA are eluted. The PT and FHA may be further purified by two sequential chromatographic columns, one of which involves apolar-ligand chromatography.

Abstract: A method of purifying granulocyte-macrophage colony-stimulating factor (GM-CSF), particularly recombinant human GM-CSF, in good yield and with retention of biological activity, comprising sequential anion-exchange, dye-ligand affinity, gel filtration and reversed-phase chromatography is disclosed.

Abstract: A method of obtaining a novel polypeptide from a crude extraction product of polysaccharide peptide Coriolus versicolor comprising: a) boiling a water soluble powder of polysaccharide peptide Coriolus versicolor; b) centrifuging a boiled product from step a); c) filtering a centrifuged product from step b); d) purifying a solution from step c) by gel filtration chromatography; e) subjecting the purified material from step d) to HPLC using a reversed-phase at ambient temperature, wherein a solvent composition is at an acidic Ph and further includes KCl solvent, and wherein an elution system consists of a linear gradient of about 80% methanol applied at a rate of from between 0-40 minutes to obtain chromatographic peaks; f) analyzing the chromatographic peaks by monitoring for absorbance at about 230 nm, 1.0 AUFS for protein analysis and about 620 nm, 0.

Abstract: The present invention relates to a vaccine derived from a bacterial or virus product that initially comprises a mixture of polymers of varying molecular weights. The vaccine contains an immunogenically effective polymer comprising T-cell-independent antigen as the effective immunizing agent. The vaccine is free of low molecular weight immunosuppressive antigen-containing polymer as a result of processing of the bacterial or virus product mixture.

Abstract: In the method for purifying factor VIII from cryoprecipitate, which is dissolved and then treated with alumina gel, the extract is diluted to a protein concentration not exceeding approximately 5 g/l and subjected to viral inactivation with solvent/detergent, the inactivated extract containing the solvent/detergent is then subjected to chromatography on a weak anion exchange column which is hydrophilic in nature and factor VIII is then eluted with a dissociating buffer.

Abstract: A method for purifying bone-derived osteoinductive factors including an ultrafiltration process, an anion exchange process, a cation exchange process, and a reverse phase HPLC process. The ultrafiltration process preferably includes a first ultrafiltration step using a membrane having a nominal molecular weight cutoff of approximately 100 kilodaltons (kD) and a second ultrafiltration step employing a membrane having a nominal molecular weight cutoff of approximately 10 kD. For the anion exchange process, a strongly cationic resin is used, preferably having quaternary amine functional groups. Typically, the eluant for the anion exchange process has a conductivity from about 10,260 micromhos (.mu.mhos) (1.026.times.10.sup.-2 siemens (S)) to about 11,200 .mu.mhos (1.120.times.10.sup.31 2 S). For the cation exchange process, a strongly anionic resin is used, preferably having sulfonic acid functional groups. The eluant for the cation exchange process typically has a conductivity from about 39,100 .mu.mhos (3.91.

Abstract: A bed of transparent, water insoluble, charge-free crosslinked gel which is suitable for use in electrophoresis is prepared. The gel is formed by dissolving a linear polysaccharide, such as agarose, in a suitable solvent, such as water. This dissolution may be accomplished with agitation. A suitable cross linking agent, which is not itself charged, nor does it become charged upon contact with water, at a pH of 2 to 12, is then added to the solution, possibly with agitation in order to get thorough mixing of the linear polysaccharide and the cross linking agent. This mixture is then allowed to incubate and react in a quiescent state to substantially simultaneously gel and crosslink to form the desired cross linked gel bed. Preferred cross-linking agents are bis-epoxides, halo-epoxides, bis-haloalkanes, bis-halo-alcohols, alkanediol-bis-alkyl sulfonates, alkanediol-bis-aryl sulfonates or divinylsulfone. The liner polysaccharide maybe mixed with a synthetic polymer such as polyvinyl alcohol.

Abstract: Immunoaffinity purifications are performed using non-aqueous media, desirably, a small amount of an aqueous buffered medium, and, optionally, a surfactant. Hydrophobic ligands can be extracted from samples, immunoaffinity purified and eluted to provide a substantially pure product.

Abstract: This invention relates to interleukin inhibitors (IL-1 INHs) that selectively inhibit interleukin 1 activity. The invention also relates to processes for purifying such IL-1 INHs from urine and for producing such IL-1 INHs by hosts transformed with recombinant DNA molecules comprising DNA sequences encoding the inhibitors, and to methods of treatment and compositions characterized by such IL-1 INHs. These methods and agents are useful in immunosuppressive and anti-inflammatory applications and therapies.

Abstract: Disclosed herein is purified isolated angiogenic factor, isolated from Live Yeast Cell Derivitive. Also disclosed herein are methods to treat mammals suffering from wounds or burns comprising administering the angiogenic factor and pharmaceutical formulations for use in the methods.

Abstract: The process for isolating albumin from supernatant IV, and in particular IV-4, or from COHN's fraction V or from a plasma supernatant or fraction of analogous composition derived from an alcoholic or nonalcoholic fractionation, comprises one step on a hydrophilic anion exchange column with binding of albumin to the column, and then elution, and one step on a hydrophobic anion exchange column. Albumin thus obtained having a purity >99% by cellulose acetate electrophoresis, being free from impurities detected by crossed immunoelectrophoresis and free from polymers.

Abstract: Recombinant protein purification vectors and methods for their use are disclosed. The vectors contain a DNA sequence coding for a gelatin binding region of fibronectin. The vectors express a foreign DNA sequence of interest fused to the fibronectin portion. Secretion signals on the fused product assist the product in being secreted from a production cell. The product can then be purified on a gelatin containing affinity column and digested with a protease such as trypsin to cleave the desired protein from the gelatin binding region. The vectors can also be designed to code for factor XIIIa cross liking sites and to have a chemically reactive cysteine residue.

Abstract: There is disclosed a complex comprised of an insoluble polymer carrier to which monomeric human albumin is covalently bound and of a pre-S hepatitis B surface antigen bound in an elutable form to the monomeric human albumin by its pre-S(2)- and/or pre-S(1)-region. This complex may be used for therapeutic and diagnostic purposes and enables the rapid and efficient purification of pre-S-HBsAg by affinity chromatography.

Abstract: Essentially pure human interleukin-6 having a purity of at least 98 % as determined by single peak migration using capillary electrophoresis is obtained by a 3-step purification method which includes a cation-exchange chromatography step, a hydrophobic chromatography step and a reverse-phase chromatography step in the presence of a charge modifier.

Abstract: The invention relates to a method of purifying basic fibroblast growth factor. The method involves the use of strong cation exchange chromatography followed by hydrophobic interaction chromatography and then by weak cation exchange chromatography.

Abstract: A novel growth factor (BTC-GF) was purified from the conditioned medium of pancreatic beta tumor cells initially derived from transgenic mice (RIPI-Tag2). The purification scheme included BioRex 70 chromatography, phenyl-Sepharose chromatography, TSL-GEL heparin FPLC and C4 reverse phase HPLC. The peptide also stimulated proliferation of bovine smooth muscle cells. It was not inactivated by boiling, by 10 mM dithiothreitol or by exposure to 1M acetic acid. Biological activity of BTC-GF was recovered from a single band of protein which had a molecular weight of 32,000 on SDS-PAGE.

Abstract: The invention provides a selective adsorbent for cellular fibronectin (cFN) and a method for fractional purification of FN which includes contacting an FN material containing plasma fibronectin (pFN) and cFN with a crosslinked polysaccharide sulfate and/or an immobilized polysaccharide sulfate to fractionate the pFN and cFN.By the fractional purification method of the invention, cFN and pFN can be fractionated in an expedient manner and with high efficiency and both pFN and cFN can be recovered in high purity and good yield.

Abstract: A process for carrying out in a consecutive fashion different modes of chromatographic separation in a liquid chromatography column using a single separation medium is disclosed. Separation media for use in such multimodal separations are also disclosed.